With regard to the anecdotal Kyprolis combination yields. I was sort of wondering whether you can comment on whether the peers can monitor whether the drug is used as a single agent or in combination setting once they provide the preauthorization?
You mentioned there are 7 oral presentations at ASH this year. Can you provide some color on that?
What is the current projections on when Kyprolis will get the product-specific reimbursement code?
Okay. In terms of Kyprolis, it's actually quite difficult for our payers or for the company, for that matter, to track whether they use as single-therapy use or in combination. So we don't really have any perspective on that one. And then I think, Barb, if you could talk a little bit about ASH.
It's only a few days that ASH will, on their website, present the information. So I don't want to get ahead of the ASH announcement. Seven oral, so one is the company-sponsored oprozomib study, the Phase I efficacy, safety data, the Kyprolis, 6 oral, both a mix of investigator-sponsored data, as well as some of our own Phase II Kyprolis information.
The permanent J Code should be available in January of 2014. These operate on a cycle prescribed by the federal government, and we expect J Code in that timing.